Compare BTG & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTG | STVN |
|---|---|---|
| Founded | 2006 | 1949 |
| Country | Canada | Italy |
| Employees | N/A | N/A |
| Industry | Precious Metals | Containers/Packaging |
| Sector | Basic Materials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.5B |
| IPO Year | 2007 | 2021 |
| Metric | BTG | STVN |
|---|---|---|
| Price | $5.03 | $21.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.00 | ★ $25.67 |
| AVG Volume (30 Days) | ★ 21.4M | 425.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.86% | 0.39% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.08 | $9.67 |
| Revenue Next Year | $28.46 | $9.99 |
| P/E Ratio | $34.75 | ★ $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.57 | $12.89 |
| 52 Week High | $6.29 | $28.00 |
| Indicator | BTG | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 67.60 | 61.62 |
| Support Level | $4.74 | $20.34 |
| Resistance Level | $5.08 | $22.00 |
| Average True Range (ATR) | 0.18 | 0.77 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 85.71 | 83.72 |
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.